Wolverine Trading, LLC Altimmune, Inc. Put Options Transaction History

Wolverine Trading, LLC

16 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$5.5 - $8.1 $57,750 - $85,050	-10,500 Reduced 21.08%	39,300 $241,000
Q2 2024 Aug 14, 2024	BUY	$5.91 - $10.23 $19,503 - $33,759	3,300 Added 7.1%	49,800 $331,000
Q1 2024 May 15, 2024	SELL	$8.22 - $13.81 $604,170 - $1.02 Million	-73,500 Reduced 61.25%	46,500 $473,000
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $225,556 - $1.22 Million	105,400 Added 721.92%	120,000 $1.35 Million
Q3 2023 Nov 15, 2023	BUY	$2.4 - $3.45 $3,840 - $5,520	1,600 Added 12.31%	14,600 $37,000
Q2 2023 Aug 23, 2023	SELL	$3.45 - $5.97 $73,485 - $127,161	-21,300 Reduced 62.1%	13,000 $45,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $90,504 - $363,527	21,600 Added 170.08%	34,300 $145,000
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $38,456 - $72,380	-4,400 Reduced 25.73%	12,700 $209,000
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $182,457 - $383,211	17,100 New	17,100 $216,000
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $245,440 - $393,119	-41,600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $9,559 - $13,728	1,100 Added 2.72%	41,600 $371,000
Q3 2021 Nov 12, 2021	BUY	$8.43 - $16.81 $121,392 - $242,063	14,400 Added 55.17%	40,500 $517,000
Q1 2021 May 14, 2021	SELL	$12.71 - $24.31 $197,005 - $376,805	-15,500 Reduced 37.26%	26,100 $354,000
Q4 2020 Feb 12, 2021	BUY	$7.84 - $14.22 $167,776 - $304,308	21,400 Added 105.94%	41,600 $470,000
Q3 2020 Nov 13, 2020	BUY	$9.93 - $33.26 $43,692 - $146,344	4,400 Added 27.85%	20,200 $263,000
Q2 2020 Aug 13, 2020	BUY	$2.9 - $10.71 $45,820 - $169,218	15,800 New	15,800 $165,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $353M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.